-
Duration of adjuvant chemotherapy for breast cancer : a joint analysis of two randomised trials investigating three versus six courses of CMFColleoni, Marco ...Cyclophosphamide, methotrexate and fluorouracil adjuvant combination chemotherapy for breast cancer is currently used for the duration of six monthly courses. We performed a joint analysis of two ... studies on the duration of adjuvant cyclophosphamide, methotrexate and fluorouracil in patients with node-positive breast cancer to investigate whether three courses of cyclophosphamide, methotrexate and fluorouracil might suffice. The International Breast Cancer Study Group Trial VI randomly assigned 735 pre- and perimenopausal patients to receive 'classical' cyclophosphamide, methotrexate and fluorouracil for three consecutive cycles, or the same chemotherapy for six consecutive cycles. The German Breast Cancer Study Group randomised 289 patients to receive either three or six cycles of i.v. cyclophosphamide, methotrexate and fluorouracil day 1, 8. Treatment effects were estimated using Cox regression analysis stratified by clinical trial without further adjustment for covariates. The 5-year disease-free survival per cents (+/-s.e.) were 54+/-2% for three cycles and 55+/-2% for six cycles (n=1024; risk ratio (risk ratio: CMFx3/CMFx6), 1.00; 95% confidence interval, 0.85 to 1.18; P=0.99). Use of three rather than six cycles was demonstrated tobe adequate in both studies for patients at least 40-years-old with oestrogen-receptor-positive tumours (n=594; risk ratio, 0.86; 95% confidence interval, 0.68 to 1.08; P=0.19). In fact, results slightly favoured three cycles over six for this subgroup, and the 95% confidence interval excluded anadverse effect of more than 2% with respect to absolute 5-year survival. In contrast, three cycles appeared to be possibly inferior to six cycles for women less than 40-years-old (n=190; risk ratio, 1.25; 95% confidence interval, 0.87 to 1.80; P=0.22) and for women with oestrogen-receptor-negativetumours (n=302; risk ratio, 1.15; 95% confidence interval, 0.85 to 1.57; P=0.37). (Source: British Journal of Cancer. - ISSN 0007-0920 (Letn. 86, št. 11, 2002, str. 1705-1714)Type of material - article, component partPublish date - 2002Language - englishCOBISS.SI-ID - 17426137
Author
Colleoni, Marco |
Lindtner, Jurij
Topics
Breast Neoplasms |
Drug Therapy |
Radiotherapy |
Mortality |
Antineoplastic Agents, Combined |
Therapeutic Use |
Administration And Dosage |
Cyclophosphamide |
Administration And Dosage |
Fluorouracil |
Administration And Dosage |
Methotrexate |
Administration And Dosage |
Adult |
Middle Age |
Chemotherapy, Adjuvant |
Disease-Free Survival |
Drug Administration Schedule |
Menopause |
Premenopause |
Survival Rate |
Time Factors |
Antineoplastiki sestavljeni |
Ciklofosfamid |
Dojka, novotvorbe |
Fluorouracil |
Metotreksat |
Brez bolezni, preživetje |
Kemoterapija pomožna |
Menopavza |
Odrasli |
Premenopavza |
Preživetje, stopnja |
Srednja leta |
Zdravilao, doziranje |
Časovni faktorji
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Colleoni, Marco | ![]() |
Lindtner, Jurij | 05278 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.